Image source: Getty Images.
Continue Reading Below
Shares of Immunomedics(NASDAQ: IMMU), an antibody-based therapeutics company, rose by more than 21% last month, according to data fromS&P Global Market Intelligence.
Interestingly enough, though, this substantial move upwards occurred without a major clinical or regulatory update. However, the company's management didpresent at three investor conferences in September, which may have attracted some much needed interest in the biopharma's anti-cancer drug development platform from institutional investors.
Continue Reading Below
Immunomedics exited the most recent quarter with roughly a year's worth of cash on hand. So, not surprisingly, management decided to take advantage of this upswing in share price to raise $30 million via a secondary offering.
All eyes are currently on Immunomedics' experimental drug, sacituzumab govitecan(IMMU-132), for third-linemetastatic triple negative breast cancer, or TNBC. The key factors at play are a possible accelerated regulatory filing forsacituzumab govitecan in TNBC that's on track for mid-2017, as well as a pivotal late-stage study slated to begin enrolling patients this December.
Immunomedics is apparently hoping the drug's encouraging mid-stage results will be enough to attract a lucrative licensing deal, whereby giving the company some additional breathing room from a financial standpoint to develop its remaining pipeline of anti-cancer agents.
While a licensing deal seems like the smartest route, Immunomedics isn't exactly in a position of strength from a bargaining standpoint. After all, the company doesn't appear to have the resources necessary to carry out a large, late-stage study for sacituzumab govitecanon its own -- that is, without halting most of its other ongoing clinical activities. So, I'd personally wait to hear the terms of any deal before buying shares of this small-cap oncology company.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.